Nanogen (NGEN) To Evaluate Strategic Alternatives for Microarray Business
More News related to NGEN
- Nanogen Enters Asset Purchase Agreement with Elitech
- Nanogen (NGEN) Reports a Q3 Loss; FY Guidance Unchanged
- Nanogen (NGEN) and The Elitech Group Announce Merger Agreement
- Nanogen (NGEN) Reports Q2 Loss of $0.07
- Nanogen (NGEN) Awarded New CDC Contract to Develop Molecular Diagnostic Test for Influenza and Avian Flu
Nanogen, Inc. (Nasdaq: NGEN) said it is evaluating strategic alternatives for its microarray business as part of an aggressive plan to achieve profitability.
The company has retained Credit Suisse to assist in the evaluation of alternatives which may include a sale, partnering or closure of the array business. The company expects to complete its evaluation of strategic alternatives within sixty to ninety days.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
